Anti-hyperlipidemic Drugs Flashcards

1
Q

Cholesterol

A

essential component of cell membranes; precursor to sterols and steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Triglyceride

A

storage form of fuel to support generation of high energy compounds; component of structural lipids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Lipoproteins transport

A

cholesterol and triglycerides in the blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the structure of lipoproteins

A

spherical particles with phospholipid, free cholesterol and protein making up surface; core made up of triglyceride and cholesterol ester

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Apoproteins on surface of lipoproteins are critical in

A

regulating transport and metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lipoprotein lipase system

A

release free fatty acids from lipoproteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Chylomicrons

A

involved in transport of dietary lipids from gut to liver and adipose tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

VLDL

A

secreted by liver into blood as a source of triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

IDL

A

triglyceride-depleted VLDLs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

LDL

A

main transport form in blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HDL

A

secreted by liver and acquire cholesterol from peripheral tissues and atheromas (reverse cholesterol transport)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ApoA-1

A

structural in HDL; ligand of ABCA1 receptor; mediates reverse cholesterol transport; produced in liver and intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ApoB-100

A

structural in VLDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ApoB-48

A

structural in chylomicrons; produced in intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ApoE

A

ligand for LDL receptor remnant receptor; reverse cholesterol transport with HDL; produced in liver and other tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ApoCIII

A

found in chylomicrons, VLDL, HDL > LDL; inhibits LPL and interferes with ApoB and ApoE binding to hepatic receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

LPL-Lipoprotein lipase

A

in capillaries of fat, cardiac and skeletal muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

LCAT

A

lethicin-cholesterol acyltransferase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CETP

A

cholesterol ester transfer protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hyperlipoproteinemia is related to

A

atherosclerosis; premature coronary artery disease; neurologic disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Hypertriglyceridemia is related to

A

pancreatitis; xanthomas; increased risk of CHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Goals of hyperlipidemia drug therapy

A

decrease reabsorption of excreted bile acids; decrease secretion of VLDL from liver; decrease synthesis of cholesterol; increase hydrolysis of lipoprotein triglycerides

23
Q

Drugs mainly for high cholesterol

A

HMG-CoA reductase inhibitors
Bile acid binding resins
Inhibitors of cholesterol absorption

24
Q

Drugs mainly for high triglycerides

A

Fibrates
Niacin
Omega 3 fatty acids

25
Ezetimibe (Zetia)
cholesterol absorption inhibitor; inhibits intestinal absorption of cholesterol from dietary sources and reabsorption of cholesterol excreted in bile (inhibits NPC1L1)
26
Indication for Ezetimibe
primary clinical effect is reduction of LDL levels; usually used in combination with statins
27
Adverse effects of Ezetimibe
low incidence of liver/skeletal muscle damage; generally well tolerated
28
HMG-CoA reductase inhibitor/Statins
Fluvastatin (Lescol), Rosuvastatin (Crestor), Atorvastatin (Lipitor); Lovastatin (Mevacor), Simvastatin (Zocor), Pravastatin (Pravachol)
29
MOA of statins
competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis
30
Indications for HMG-CoA reductase inhibitors
hypercholesterolemia: elevated LDL; elevated LDL with slightly elevated TGs standard to initiate therapy immediately after MI, irrespective of lipid levels
31
Dosing of Lovastatin
should be taken with evening meal to facilitate absorption
32
Dosing of Rosuvastatin, Atorvastatin, and Pravachol
taken as a single dose any time of the day
33
Dosing of Fluvastatin XL
can be taken as a single dose any time of the day
34
Metabolism of Lovastatin, Simvastatin and Atorvastatin
CYP3A4; tends to accumulate in presence of drugs that inhibit or compete for CYP 3A4 (macrolide antibiotics, cyclosporine, ketoconazole; grapefruit juice)
35
Prodrug statins
Lovastatin and Simvastatin
36
Metabolism of Fluvastatin and Rosuvastatin
inhibitors may increase plasma levels: cimetidine, metronidazole and amiodarone
37
Metabolism of Pravastatin
sulfation
38
Adverse effects of HMG-CoA reductase inhibitors
Rhabdomyolysis with renal dysfunction secondary to myoglobinuria; dose related phenomenon; monitor serum creatinine phosphokinase; increased incidence when co-administered with CYP inhibitors; may occur with gemfibrozil Hepatotoxicity: monitor serum transaminase activity
39
Juxtapid (Lomitapide)
inhibits assembly of ApoB containing lipoproteins in liver and intestine; interferes with the ability to absorb dietary lipids and fat-soluble vitamins
40
Indications for Juxtapid
indicated as adjunct to other treatments for patients with homozygous familial hypercholesterolemia - LDLR mutation
41
Mipomersen (Kynamro)
phosphorothioate anti-sense oligonucleotide inhibitor of apoB 100; hybridizes Apo B100 mRNA in liver and promotes degradation
42
Indications for Mipomersen
indicated as adjunct to other treatments for patients with homozygous familial hypercholesterolemia
43
Fibrates bind to
PPAR-alpha and regulted gene transcription along with the retinoic acid receptor (RXR)
44
Therapeutic indications for fibric acid derivates
hypertriglyceridemia in which VLDL predominate; second line drug for mixed hyperlipidemia
45
Side effects of fibric acid derivatives
gallstones; skeletal muscle effects - rhabdomyolysis
46
Lovaza
combination of ethyl esters of omega-3-fatty acid
47
Lovaza MOA
reduce synthesis of triglyceride in liver: omega-3 fatty acids are poor substrates for enzymes responsible for TG synthesis; inhibit esterification of other fatty acids
48
Therapeutic indications for omega-3 fatty acids
lipid lowering diet is initiated before Lovaza therapy is started; severe hypertriglyceridemia >500 mg/dl
49
MOA of Niacin
reduces serum triglycerides; increases lipase activity to increase clearance of VLDL; decreases hepatic VLDL production; may significantly reduce serum LDL and TG; usually increases HDL levels
50
What does Niacin do in adipose tissue?
inhibits TG lipolysis by hormone-sensitive lipase; decreaseing FA transport to liver; via activation of GPR109A
51
What does Niacin do in the liver?
inhibits FA synthesis and esterification; reducing TG export via VLDL; reduces clearance of apoA-1 but no CEs; increases HDL levels and reverse transport
52
What does Niacin do to macrophages?
increases expression of CD36 and ABCA1; decreasing CE content via HDL0mediated reverse transport
53
Indications for Niacin
effective for mixed hyperlipidemias; effective drug for raising HDL levels; used in combo with resin drugs to treat severe cases of hyperlipidemia; also combined with statins
54
Adverse effects of Niacin
``` marked vasodilation (cutaneous flushing), itching, tingling of upper body and headache may occur with initial dosing - prostaglandins mediate these (treat with aspirin or ibuprofen) hepatotoxicity ```